(Q27853351)

13 November 2016

title

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report (English)

1 reference

PubMed

Proceedings of the National Academy of Sciences of the United States of America

13 November 2016

1 reference

1 reference

Funda Meric-Bernstam

0 references

author name string

Vivek Subbiah

series ordinal

0 references

David S Hong

series ordinal

0 references

language of work or name

English

0 references

publication date

15 March 2016

0 references

published in

0 references

volume

113

0 references

issue

0 references

page(s)

E1419-20

0 references

cites work

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4801313

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

20 March 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4801313

Ceritinib in ALK-rearranged non-small-cell lung cancer

20 March 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4801313

The Signature Program: Bringing the Protocol to the Patient

20 March 2017

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1522052113

21 January 2018

Identifiers

DOI

10.1073/PNAS.1522052113

0 references

0 references

1 reference

13 November 2016

1 reference

PubMed